Philadelphia, PA. – May 31, 2019 – Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology has expanded its relationship with WuXi AppTec’s Advanced Therapies Business...
The new facility will more than double testing capacity for cell and gene therapies. On November 1, 2018, Liberty Property Trust and Synterra Partners held a groundbreaking ceremony to kick off the construction of our fourth building in the Philadelphia Navy Yard. The...
WuXi AppTec Advanced Therapies will manufacture Nohla’s cell therapies at their Philadelphia Navy Yard campus, which features over 220,000 square feet of GMP compliant manufacturing space. Nohla Therapeutics, a leading developer of universal donor cell therapies...
